Quantcast

Latest Actavis Stories

2014-06-09 20:22:33

- Terms Unchanged from Previously Disclosed Agreement - DUBLIN, June 9, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has finalized its previously announced agreement with Zydus Pharmaceuticals USA Inc. to settle all outstanding patent litigation related to Zydus' generic version of Asacol(®) HD (mesalamine) delayed-release tablets. The terms of the agreement are unchanged from those disclosed by the companies in December 2013. Under the terms of the...

2014-06-09 08:28:52

DUBLIN, June 9, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) (the "Company") today announced that it has extended the expiration date of its offer to guarantee the outstanding debt securities listed in the table below (the "FRX Notes") of Forest Laboratories, Inc. (NYSE: FRX) in exchange for the elimination of the existing registration rights obligations with respect to each of those debt securities (the "Consent Solicitations"). The Consent Solicitations were originally scheduled to...

2014-05-30 16:25:02

DUBLIN, May 30, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has entered into an agreement with Cephalon, Inc. to settle all outstanding patent litigation related to Actavis' generic version of Nuvigil(® )(armodafinil tablets, 50 mg, 100 mg, 150 mg, 200 mg and 250 mg). Nuvigil(®) is a prescription medicine indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), shift work disorder (SWD) or...

2014-05-27 16:25:33

DUBLIN, May 27, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Saxagliptin Hydrochloride Tablets, 2.5 mg and 5 mg. Actavis' ANDA product is a generic version of AstraZeneca and Bristol-Myers Squibb's Onglyza(®), which is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes....

2014-05-23 08:24:32

CHAGRIN FALLS, Ohio, May 23, 2014 /PRNewswire/ -- EnzymeBioSystems (OTCBB: ENZB) (OTCQB: ENZB), announces the appointment of Gary Rojewski as its new CEO, effective June 2, 2014. Mr. Rojewski will be responsible for leading and managing EnzymeBioSystems' business operations, including regulatory affairs with government agencies. Mr. Rojewski has 29-years experience in the pharmaceutical industry. During that time he has worked for Procter and Gamble Pharmaceuticals (PG), Warner...

2014-05-22 08:30:15

DUBLIN, May 22, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that, subject to the close of its pending acquisition (the "Acquisition") of Forest Laboratories, Inc. (NYSE: FRX), it is offering to guarantee certain of Forest's outstanding debt securities in exchange for the elimination of the existing registration rights obligations with respect to those outstanding debt securities. Forest is soliciting consents ("Consents") from holders of its securities listed in the...

2014-05-21 08:29:22

DUBLIN, May 21, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/78cbh2/global_pva_drugs) has announced the addition of the "Global PVA Drugs Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 Vaginal atrophy is defined as a decrease in estrogen production. Less estrogen leads to thinning, drying, and decreased elasticity of the vaginal tissues. PVA is defined as the decrease in estrogen after menopause. Up to...

2014-05-15 08:33:22

DUBLIN, May 15, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has reached an agreement with Janssen Pharmaceuticals, Inc. (JPI) to continue supplying the authorized generic version of JPI's Concerta(®) (methylphenidate hydrochloride extended-release tablets). Under the terms of the extended exclusive supply and distribution agreement -- which was first agreed to by the companies in November 2010 and due to expire on December 31, 2014 -- JPI will continue to...

2014-05-14 08:31:00

- Paul Bisaro to Assume Newly Created Role as Executive Chairman - DUBLIN, May 14, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced the proposed senior management team that will lead the specialty pharmaceutical company pending the successful close of the acquisition of Forest Laboratories, Inc., which is anticipated at mid-year. Following the close, Paul Bisaro, Chairman and Chief Executive Officer of Actavis, will become Executive Chairman. Brent Saunders,...

2014-05-13 16:29:25

DUBLIN, May 13, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has received final approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for a generic version of Mallinckrodt Inc.'s Exalgo(®) (Hydromorphone Hydrochloride Extended-release Tablets 8 mg, 12 mg and 16 mg). Actavis intends to begin shipping its product shortly and believes that, under applicable Hatch Waxman rules, it may be entitled to marketing exclusivity....


Word of the Day
baudekin
  • A rich embroidered or brocaded silk fabric woven originally with a warp of gold thread.
'Baudekin' seems to be an alternative form of 'baldachin,' from the Italian 'Baldacco,' Baghdad, the city where the material was made.
Related